RVT-101 for Dementia with Lewy Bodies (HEADWAY-DLB)


Axovant Sciences, have announced their decision to discontinue the HEADWAY-DLB study. The Lewy Body Society is obviously very disappointed at this news and especially for those of our supporters who took part in the trials. The project tested the efficacy and safety of the experimental drug RVT-101, also known as interpirdine, in people with dementia with Lewy bodies, by measuring its effect on cognitive, motor and global function, as well as on visual hallucinations.

The press release from AXOVANT, found here:
https://http://investors.axovant.com/news-releases/news-release-details/axovant-announces-negative-results-intepirdine-phase-2b-headway/ summarises the main findings which did not include any statistically significant benefits of the investigational drug, over and above placebo after 24 weeks of treatment.
Further information including a comment from Lewy Body Society president Professor Ian McKeith can be found at https://www.alzforum.org/news/research-news/dlb-intepirdine-no-go-nelotanserin-shrouded-controversy/

We hope that the successful completion of this study will encourage other similar studies to be established since this is the only way in which effective therapy for DLB will be developed.